Minneapolis Heart Institute Foundation

Prevention Research / Nolan Family Center for Cardiovascular Health

April 2026 Bi-Annual Update

View as Webpage

News & Updates

Join us for At the Heart of Cardiovascular Disease Prevention 2026! Click for more information on topics and registration.
The Nolan Center Team has added two more patient videos, How to Prevent and Treat High Blood Pressure and Unique Risk Factors for Heart Disease in Women to its virtual educational library.

Study Spotlight: MARITIME-CV

Description

This study compares study medication (GLP-1) to placebo on cardiovascular outcomes in participants living with overweight or obesity and atherosclerotic cardiovascular disease.

To be eligible for this study, individuals must be ≥ 45 years at screening, have a BMI ≥ 27 kg/m2 and a history of ASCVD (e.g. prior heart attack, prior stroke or symptomatic peripheral arterial disease).

Contact

Isabel Dwyer

Isabel.dwyer@allina.com

Principal Investigator

Dr. Michael Miedema

Enrolling Clinical Studies

Study

Study Intervention

PI and Enrolling Sites

TRANSFORM

Cleerly

Cleery CAD stage-based care strategy

Dr. Michael Miedema

ANW and Eden Prairie clinics

MARITIME-CV

Amgen

GLP-1/GIPR combination product (injection) in patients with ASCVD

Dr. Michael Miedema

ANW and Eden Prairie clinics

MAVERIC

Cardiol Therapeutics

Cannabidiol (CardiolRx) (anti-inflammatory application) or placebo for 6 months for patients with Recurrent Pericarditis

Dr. David Lin

ANW

DESIFOR EXPAND

MHIF

Patients previously intolerant of statins serve as their own controls while taking blinded placebo/rosuvastatin

Dr. Michael Miedema

ANW, Eden Prairie, Chaska and Edina clinics

Pipeline Studies

KPL-387-C211

Kiniksa

Monthly KPL-387 (IgG2 monoclonal antibody) or placebo injection for patients with Recurrent Pericarditis

Dr. David Lin

ANW

Abbreviations: ANW= Abbot Northwestern Hospital; ASCVD= atherosclerotic cardiovascular disease; CV= cardiovascular; CAD= coronary artery disease; GLP= glucagon like peptide; LDL= low density lipoprotein

For more information, please contact Shannon Clark at Shannon.Clark@allina.com

Interested in clinical trials from our other areas of cardiovascular research? Visit mplsheart.org/archive for any recent emails you may have missed.